Roadmap for ending TB in China by 2035: The challenges and strategies.

IF 5.7 4区 生物学 Q1 BIOLOGY
Bioscience trends Pub Date : 2024-03-19 Epub Date: 2024-02-08 DOI:10.5582/bst.2023.01325
Qishun Feng, Guoliang Zhang, Liang Chen, Huizhong Wu, Yingzhou Yang, Qian Gao, Tetsuya Asakawa, Yanlin Zhao, Shuihua Lu, Lin Zhou, Hongzhou Lu
{"title":"Roadmap for ending TB in China by 2035: The challenges and strategies.","authors":"Qishun Feng, Guoliang Zhang, Liang Chen, Huizhong Wu, Yingzhou Yang, Qian Gao, Tetsuya Asakawa, Yanlin Zhao, Shuihua Lu, Lin Zhou, Hongzhou Lu","doi":"10.5582/bst.2023.01325","DOIUrl":null,"url":null,"abstract":"<p><p>Tuberculosis (TB) is one of the top ten causes of death worldwide, taking the lives of over a million people annually. In addition to being a serious health issue, TB is also closely linked to eradicating poverty according to the Sustainable Development Goals (SDGs) of the United Nations (UN). All UN members have committed to ending the TB epidemic by 2030. China has one of the highest TB loads worldwide, ranking third in the world on many TB burden indices. The national strategy for TB control is aimed at creating a collaborative network and integrating TB treatment into the medical system. According to the WHO's global TB report, China is expected to have 748,000 new cases of TB in 2022 and an incidence of 52 cases per 100,000 people. Ending TB remains a huge challenge and requires comprehensive control strategies in China. In this work, we have discussed the challenges of TB prevention and control in China and proposed specific measures to end TB.</p>","PeriodicalId":8957,"journal":{"name":"Bioscience trends","volume":" ","pages":"11-20"},"PeriodicalIF":5.7000,"publicationDate":"2024-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Bioscience trends","FirstCategoryId":"99","ListUrlMain":"https://doi.org/10.5582/bst.2023.01325","RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/2/8 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"BIOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Tuberculosis (TB) is one of the top ten causes of death worldwide, taking the lives of over a million people annually. In addition to being a serious health issue, TB is also closely linked to eradicating poverty according to the Sustainable Development Goals (SDGs) of the United Nations (UN). All UN members have committed to ending the TB epidemic by 2030. China has one of the highest TB loads worldwide, ranking third in the world on many TB burden indices. The national strategy for TB control is aimed at creating a collaborative network and integrating TB treatment into the medical system. According to the WHO's global TB report, China is expected to have 748,000 new cases of TB in 2022 and an incidence of 52 cases per 100,000 people. Ending TB remains a huge challenge and requires comprehensive control strategies in China. In this work, we have discussed the challenges of TB prevention and control in China and proposed specific measures to end TB.

到 2035 年在中国消除结核病的路线图:挑战与战略。
结核病(TB)是全球十大死因之一,每年夺走 100 多万人的生命。结核病不仅是一个严重的健康问题,根据联合国的可持续发展目标(SDGs),它还与消除贫困密切相关。所有联合国会员国都承诺到 2030 年消除结核病疫情。中国是世界上结核病发病率最高的国家之一,在多项结核病负担指数中排名世界第三。国家结核病控制战略旨在建立一个协作网络,并将结核病治疗纳入医疗体系。根据世界卫生组织的全球结核病报告,预计到 2022 年,中国将新增结核病病例 74.8 万例,发病率为每 10 万人 52 例。消除结核病仍然是一项巨大的挑战,需要中国采取全面的控制策略。在这项工作中,我们探讨了中国结核病防控面临的挑战,并提出了终结结核病的具体措施。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
13.60
自引率
1.80%
发文量
47
审稿时长
>12 weeks
期刊介绍: BioScience Trends (Print ISSN 1881-7815, Online ISSN 1881-7823) is an international peer-reviewed journal. BioScience Trends devotes to publishing the latest and most exciting advances in scientific research. Articles cover fields of life science such as biochemistry, molecular biology, clinical research, public health, medical care system, and social science in order to encourage cooperation and exchange among scientists and clinical researchers.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信